Who
Robert A. Stewart
Director
Company insider
Files Form 4 as: Director, CorMedix; President and CEO, Amneal Pharmaceuticals; Chief Operating Officer, Allergan; Pres-Global Operations, Actavis.
In numbers
- Trades disclosed
- 53
- Buys
- 2
- Sells
- 4
- Bought
- $246K
- Sold
- $6.9M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 16 Nov 2009
- Last trade
- 26 Jan 2026
- Last filed
- 27 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —30,453 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —30,453 at $0.00 | filing |
| 17 Jan 2025filed 22 Jan 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Mar 2024filed 20 Mar 2024 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 17 May 2023filed 18 May 2023 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Bought | $44K10,000 at $4.37 | filing |
| 17 May 2023filed 17 May 2023 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | $44K10,000 at $4.37 | filing |
| 13 Apr 2023filed 17 Apr 2023 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 13 Apr 2023filed 17 Apr 2023 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —14,200 at $0.00 | filing |
| 7 May 2019filed 9 May 2019 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —83,277 at $0.00 | filing |
| 7 May 2019filed 9 May 2019 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —83,277 | filing |
| 7 May 2019filed 9 May 2019 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $290K21,609 at $13.44 | filing |
| 12 Mar 2019filed 12 Mar 2019 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $203K17,000 at $11.92 | filing |
| 1 Mar 2019filed 5 Mar 2019 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —402,212 at $0.00 | filing |
| 1 Mar 2019filed 5 Mar 2019 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —197,531 at $0.00 | filing |
| 7 May 2018filed 9 May 2018 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —681,199 at $0.00 | filing |
| 7 May 2018filed 9 May 2018 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —333,111 at $0.00 | filing |
| 29 Dec 2017filed 2 Jan 2018 | Allergan | SEC FORM 4 Code F | $352K2,149 at $163.58 | filing |
| 26 Oct 2017filed 30 Oct 2017 | Allergan | SEC FORM 4 Code M | —12,427 | filing |
| 26 Oct 2017filed 30 Oct 2017 | Allerganoption or derivative | SEC FORM 4 Code M | —12,427 | filing |
| 3 Apr 2017filed 4 Apr 2017 | Allergan | SEC FORM 4 Code A | $1.7M7,362 at $237.68 | filing |
News
Contrasting CorMedix (NASDAQ:CRMD) & InMed Pharmaceuticals (NASDAQ:INM)CRMD · themarketsdaily.com · 22 Oct 2026Head-To-Head Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus CorMedix (NASDAQ:CRMD)CRMD · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Robert A. Stewart; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.